Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Nuclear expression of Glycogen synthase kinase-3 beta and lack of membranous beta-catenin is correlated with poor survival in colon cancer

In English

Författare

Summary, in English

Dysregulation of Wnt/beta-catenin signaling is a hallmark of colon cancer. Glycogen synthase kinase-3 beta (GSK-3 beta) can be a positive regulator of survival and proliferation of cultured colon cancer cell but its role in clinical colon cancer is unknown. Our objectives were to evaluate the role of GSK-3 beta in colon cancer. A tumor tissue microarray of primary colon cancers and metastases was used to evaluate expression and subcellular localization of GSK-3 beta and beta-catenin. In total, 85 primary colon cancer samples were evaluated by immunohistochemistry. Immunoreactivity was correlated to known markers of adverse prognosis. Overall survival was the primary end-point. We found nuclear accumulation of GSK-3 beta in 39% (33/85) of evaluated tumors. Nuclear GSK-3 beta was significantly associated with shorter overall survival (p=0.008), larger tumor size (p=0.015), distant metastasis (p=0.029) and loss of membranous beta-catenin (p=0.007). Loss of membranous beta-catenin occurred in 37% (30/82) of the tumors and was associated with poor survival (p=0.016). The combination of nuclear GSK-3 beta and lack of membrane beta-catenin occurred in a total of 26% of the studied tumors (21/61) and was significantly and independently associated with poor prognosis. Our results suggest that nuclear expression of GSK-3 beta and loss of membrane beta-catenin identify a subset of colon carcinomas with worse prognosis.

Avdelning/ar

Publiceringsår

2013

Språk

Engelska

Sidor

807-815

Publikation/Tidskrift/Serie

International Journal of Cancer

Volym

133

Issue

4

Dokumenttyp

Artikel i tidskrift

Förlag

John Wiley & Sons Inc.

Ämne

  • Cancer and Oncology

Nyckelord

  • GSK-3 beta
  • beta-catenin
  • colon cancer
  • metastasis
  • survival

Status

Published

Forskningsgrupp

  • Cell Pathology, Malmö
  • Surgery

ISBN/ISSN/Övrigt

  • ISSN: 0020-7136